Extended Data Figure 4: Activity of ABL001 and nilotinib in KCL-22 cell clones expressing Thr315Ile and Ala337Val BCR–ABL1 variants.
From: The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
a, The sensitivity of parental KCL-22 cells (WT) and KCL-22-resistant clones expressing BCR–ABL1 Ala337Val and Thr315Ile mutation variants to treatment with ABL001 (left) and nilotinib (right) was tested in 72 h growth assays. Samples were tested in duplicate; data are mean ± s.d. as a percentage of the vehicle-treated cells. b, KCL-22 Thr315Ile mutant cells were implanted as mouse xenografts and the efficacy of ABL001 across a dose range of 3–30 mg kg−1 BID was determined. Nilotinib was tested at 75 mg kg−1 BID as a control. Data are mean ± s.e.m. (n = 7 per group). T/C denotes ratio of tumour volume in control versus treated mice; ‘Reg’ denotes regression.
